Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 5/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279643 | 0.86 | RECQL (0.43) | RECQLMAP2K1NAMPTHRH4ALDH1A1 | |
| SCHEMBL4275790 | 0.86 | RECQL (0.50) | RECQLNAMPTALDH1A1LMNAMAPT | |
| SCHEMBL4274096 | 0.76 | MAP2K1 (0.51) | MAP2K1NAMPTHRH4RBP4HDAC1 | |
| SCHEMBL4271243 | 0.75 | RECQL (0.57) | RECQLNAMPTALDH1A1LMNAMAPT | |
| SCHEMBL4276540 | 0.74 | RECQL (0.56) | RECQLNAMPTALDH1A1LMNAMAPT | |
| SCHEMBL4266959 | 0.69 | RECQL (0.50) | RECQLNAMPTALDH1A1LMNAMAPT | |
| SCHEMBL4272549 | 0.68 | MAP2K1 (0.68) | MAP2K1HRH4MAPTRBP4HDAC1 | |
| SCHEMBL20417734 | 0.66 | RECQL (0.68) | RECQLALDH1A1LMNAMAPTHDAC1 | |
| SCHEMBL4271447 | 0.66 | DAO (0.41) | HRH4MAPT | |
| SCHEMBL4273734 | 0.65 | MAPT (0.57) | RECQLNAMPTALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064715-A1 | 6-Azaindole Compound | RELA, NFKBIA, GPR119 | RECQL 1543/4885MAP2K1 551/4885NAMPT 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.